$PFSA

HRT FINANCIAL LP sold $2K of PFSA

HRT FINANCIAL LP sold 2,280 shares of Profusa, Inc. (PFSA) at $0.97 on 2026-08-11.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 12, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 7:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Neutral
high confidence
Mentioned
$PFSA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

A 10% owner open-market sale is disclosed, but there is no accompanying fundamental update (no earnings, guidance, deal, or regulatory action).

02

Market read

Traders may note the sale for sentiment, but the disclosed size and lack of fundamental news make it low priority.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not provide intent or a fundamental catalyst.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-12, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA).

Company-level read

Ticker impact

$PFSANeutralHigh confidence
Context

Profusa, Inc. (PFSA) disclosed via Form 4 that HRT Financial LP sold 2,280 shares at $0.9700 on 2026-08-11.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades quickly.

Evidence & confidence

The filing is a Form 4 transaction (not a guidance, contract, or enforcement event) and the disclosed sale value is only about $2.2k, with no 10b5-1 plan cited.

Market effects

No clear sector read-through from a small 10% owner open-market sale.

None indicated.

None indicated.

Counterpoint

Even small sales can reflect liquidity needs or tax planning, so the market may overinterpret the signal.

Key entities

  • Profusa, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • HRT Financial LP

    Reporter and 10% owner who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.